UK Users

Access Prodigy topics and clinical content at the NICE website.

Visit the NICE website

Free Trial

To arrange a free trial of the Prodigy application, get in touch.

Contact us to arrange a trial

International Users

The Prodigy application is available on a subscription basis.

Subscription types

Sample Topic: Asthma

Asthma : Last revised in December 2013


Changes

December 2013 — minor update. A broken link to the Children’s Asthma Control Test has been fixed.

July 2013 — minor update. Links to the DVLA website have been updated.

June 2013 — minor update. The 2013 QOF options for local implementation have been added to this topic [BMA and NHS Employers, 2013].

May 2013 — minor update. Minor change to the text to improve the clarity of how to manage people who are awaiting hospital admission.

February 2013 — minor update. The 2013 QIPP options for local implementation have been added to this topic [NICE, 2013].

October 2012 — minor update. The 2012 QIPP options for local implementation have been added to this topic [NPC, 2012].

March 2012 — minor update. The 2012/2013 QOF indicators have been added to this topic [BMA and NHS Employers, 2012]. Issued in April 2012.

February 2012 — minor update. A recommendation to advise people inhaling terbutaline via a turbohaler to rinse their mouth after each use to minimize systemic adverse effects has been added, following an update to the manufacturer’s Summary of Product Characteristics [ABPI Medicines Compendium, 2011b]. Issued in March 2012.

November 2011 — minor update. The black triangle has been removed from Serevent Evohaler® (salmeterol cfc-free inhaler); prescriptions have been amended to reflect this. Issued in December 2011.

June 2011 — annual updates from the British guideline on the management of asthma: a national clinical guideline by SIGN/BTS are now included [SIGN and BTS, 2011]. Issued in June 2011.

May 2011 — minor update. The 2011/2012 QOF indicators and the 2010/2011 QIPP options for local implementation have been added to this topic [BMA and NHS Employers, 2011; NPC, 2011]. Issued in June 2011.

April 2011 — minor update. Pulmicort pMDI inhalers have been removed from this topic as they have been discontinued. Issued in June 2011.

March 2011 — topic structure revised to ensure consistency across Prodigy topics — no changes to clinical recommendations have been made.

February 2011 — minor update. The range of dry powder inhaler devices included as prescriptions has been updated. Issued in February 2011.

December 2010 — minor update. The Flixotide Diskhaler® (fluticasone) range has been discontinued. The prescription has been removed. Issued in December 2010.

October 2010 — minor update. Information on fitness to drive from the Driver and Vehicle Licensing Agency’s guidance for medical practitioners, At a glance guide to the current medical standards of fitness to drive has been added [DVLA, 2010]. Issued in November 2010.

September 2010 — minor update. The Medicines and Healthcare products Regulatory Agency has issues a reminder to prescribers that, for most children, a daily dose of 24 micrograms formoterol is sufficient [MHRA, 2010]. Issued in September 2010.

March 2010 — minor update. All strengths of Beclazone® inhalers have been discontinued. Prescriptions removed. For advice regarding switching from CFC beclometasone to CFC-free beclometasone, see the section What dose of inhaled corticosteroid should I prescribe? FIX LINK!!!. Issued in March 2010.

January 2010 – minor update. Ciclesonide (Alvesco®) is no longer a black triangle product. Minor addition to text regarding drug interactions with theophylline. Issued in January 2010.

December 2009 — minor update. Clenil Modulite® (beclometasone CFC-free) is no longer a black triangle product. Prescription updated. Issued in December 2009.

November 2009 — minor update. The Supporting evidence section on Symbicort Smart® FIX LINK!!! has been reworded to make it clear that the data summarized are from a single Cochrane review. Issued in November 2009.

August 2009 — minor update. The annual updates from the British guideline on the management of asthma: a national clinical guideline by SIGN/BTS are now included [SIGN and BTS, 2008b]. Issued in August 2009.

May 2009 — updated to include information and prescriptions for budesonide CFC-free pMDI. The Nebuhaler® spacer device has been discontinued. The prescription has been replaced with the NebuChamber® spacer device. Issued in June 2009.

April 2009 — minor update. The Quality and Outcomes Framework (QOF) indicators for stopping smoking that relate to asthma have been added to the Goals and outcome measures section. Issued in May 2009.

February 2009 — minor update. Flixotide® 50 microgram diskhaler and all strengths of the Aerobec® breath-actuated inhaler have been discontinued. Prescriptions removed. Issued March 2009.

August 2008 — update to the diagnosis and assessment sections following the publication of the British guideline on the management of asthma: a national clinical guideline by SIGN/BTS [SIGN and BTS, 2008a]. Issued in November 2008.

March 2008 — minor update to include advice from the Medicines and Healthcare products Regulatory Agency (MHRA) regarding the use of short-acting beta2-agonists in people who have a history of heart disease. Issued in March 2008.

September to December 2007 — converted from Prodigy guidance to Prodigy topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.

This Prodigy topic includes revisions in the 2007 update to the SIGN/BTS British Guideline on the Management of Asthma.